Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights

摘要: Abstract Elderly patients with glioblastoma are characterized by a high rate of associated morbidities, and poor prognosis. Therefore, they have been excluded from most prospective clinical trials. However, the poorer outcome retrospectively reported in these might be also related to that those less likely receive appropriate treatment than their younger counterparts. We reviewed literature regard optimal therapeutic management this particular population, focus on molecular perspectives for improving patients’ selection. Clinical data demonstrated open craniotomy resection tumor was superior biopsy only elderly good Karnofsky Performance Status (KPS) score. Then, postoperative radiotherapy (RT) improves survival without impairing functional status or neurocognitive functions, compared best supportive care following resection. Despite promising preliminary data, addition concomitant temozolomide RT has not validated more 70-years old. In case additional prognostic factors after only, there is no definitive demonstration RT, chemotherapy, both could improve outcome. Incorporation sensitive predictive and/or help physicians Further trials should incorporate age-dependent specificities design, better subgroup exhibiting specific alterations.